Učitavanje...
Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?
Sodium glucose co‐transporter‐2 inhibitors have attracted the interest of the scientific community following the results from dedicated cardiovascular outcome trials, which demonstrated remarkable reduction in all‐cause mortality and other cardiovascular (CV) endpoints with empagliflozin and canagli...
Spremljeno u:
| Izdano u: | Diabetes Obes Metab |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Blackwell Publishing Ltd
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6283243/ https://ncbi.nlm.nih.gov/pubmed/30003655 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13468 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|